High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 6, 2008, Pages 622-630

  Young, Faith M ^a   Campbell, Andrew ^a   Emo, Kris Lambert ^a   Jansson, Johan ^a   Wang, Pin Yi ^a   Jordan, Craig T ^a   Mullen, Craig A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplant; Cytolytic T cell; Graft versus leukemia; Minor histocompatibility antigene; Oncogene

Indexed keywords

ARF PROTEIN; BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MINOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL GROWTH; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GENE MUTATION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HLA MATCHING; HYPOTHESIS; IMMUNE RESPONSE; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOBLAST; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY IMMUNE RESPONSE; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; GENES, ABL; GENES, P16; GRAFT VS LEUKEMIA EFFECT; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINOR HISTOCOMPATIBILITY ANTIGENS; MODELS, IMMUNOLOGICAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RADIATION CHIMERA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 43449120115     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.015     Document Type: Article

References (26)

1. Collins R.H.J., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15 (1997) 433-444
2. Collins Jr. R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 26 (2000) 511-516
3. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 (1995) 2041-2050
4. Peggs K.S., and Mackinnon S. Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 8 (2001) 349-354
5. Kolb H.-J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
6. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 (2004) 4010-4022
7. Heerema N.A., Harbott J., Galimberti S., et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 18 (2004) 693-702
8. + adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 19 (2005) 713-720
9. Sharpless N.E., and Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576 (2005) 22-38
10. Williams R.T., Roussel M.F., Sherr C.J., Williams R.T., Roussel M.F., and Sherr C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103 (2006) 6688-6693
11. Shank-Calvo J.A., Draheim K., Bhasin M., et al. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene 25 (2006) 3023-3031
12. Bianchi T., Rufer N., MacDonald H.R., et al. The tumor suppressor p16Ink4a regulates T lymphocyte survival. Oncogene 25 (2006) 4110-4115
13. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., and DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 (1996) 27-37
14. Green M.C., and Witham B.A. Handbook on Genetically Standardized Jax Mice. 4 ed. (1991), Jackson Laboratory, Bar Harbor, ME
15. Neering S.J., Bushnell T., Sozer S., et al. Leukemia stem cells in a genetically defined murine model of blast phase CML. Blood 110 (2007) 2578-2585
16. Case S.S., Price M.A., Jordan C.T., et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96 (1999) 2988-2993
17. Jordan C.T. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 16 (2002) 559-562
18. Dash A.B., Williams I.R., Kutok J.L., et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 99 (2002) 7622-7627
19. LaBelle J.L., Truitt R.L., LaBelle J.L., and Truitt R.L. Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia. Leukemia Lymphoma 43 (2002) 1637-1644
20. Anderson L.D., Savary C.A., and Mullen C.A. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 95 (2000) 2426-2433
21. Anderson L.D., Mori S., Mann S., Savary C.A., and Mullen C.A. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 60 (2000) 5797-5802
22. Anderson L.J., Petropoulos D., Everse L.A., and Mullen C.A. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Cancer Res 59 (1999) 1525-1530
23. Mori S., El-Baki H., and Mullen C.A. An analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 31 (2003) 865-875
24. Natzke A.M., Shaw J.L., McKeller M.R., et al. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease. Biol Blood Marrow Transplant 13 (2007) 34-45
25. Hardy R.R., Kincade P.W., Dorshkind K., Hardy R.R., Kincade P.W., and Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity 26 (2007) 703-714
26. Young F., Ardman B., Shinkai Y., et al. Influence of immunoglobulin heavy- and light-chain expression on B-cell differentiation. Genes Dev 8 (1994) 1043-1057